These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

255 related articles for article (PubMed ID: 33328392)

  • 1. Chimeric Antigen receptor-T (CAR-T) cells targeting Epithelial cell adhesion molecule (EpCAM) can inhibit tumor growth in ovarian cancer mouse model.
    Fu J; Shang Y; Qian Z; Hou J; Yan F; Liu G; Dehua L; Tian X
    J Vet Med Sci; 2021 Mar; 83(2):241-247. PubMed ID: 33328392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical Evaluation of Chimeric Antigen Receptor-Modified T Cells Specific to Epithelial Cell Adhesion Molecule for Treating Colorectal Cancer.
    Zhang BL; Li D; Gong YL; Huang Y; Qin DY; Jiang L; Liang X; Yang X; Gou HF; Wang YS; Wei YQ; Wang W
    Hum Gene Ther; 2019 Apr; 30(4):402-412. PubMed ID: 30693795
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies.
    Jie Y; Liu G; Feng L; Li Y; E M; Wu L; Li Y; Rong G; Li Y; Wei H; Gu A
    Front Immunol; 2021; 12():665970. PubMed ID: 34475869
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bispecific CAR T Cells against EpCAM and Inducible ICAM-1 Overcome Antigen Heterogeneity and Generate Superior Antitumor Responses.
    Yang Y; McCloskey JE; Yang H; Puc J; Alcaina Y; Vedvyas Y; Gomez Gallegos AA; Ortiz-Sánchez E; de Stanchina E; Min IM; von Hofe E; Jin MM
    Cancer Immunol Res; 2021 Oct; 9(10):1158-1174. PubMed ID: 34341066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intraperitoneal immunotherapy with T cells stably and transiently expressing anti-EpCAM CAR in xenograft models of peritoneal carcinomatosis.
    Ang WX; Li Z; Chi Z; Du SH; Chen C; Tay JC; Toh HC; Connolly JE; Xu XH; Wang S
    Oncotarget; 2017 Feb; 8(8):13545-13559. PubMed ID: 28088790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of a Novel Third-Generation Anti-CD24-CAR against Ovarian Cancer.
    Klapdor R; Wang S; Morgan M; Dörk T; Hacker U; Hillemanns P; Büning H; Schambach A
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717444
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive T-cell therapy of prostate cancer targeting the cancer stem cell antigen EpCAM.
    Deng Z; Wu Y; Ma W; Zhang S; Zhang YQ
    BMC Immunol; 2015 Jan; 16(1):1. PubMed ID: 25636521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models.
    Zhang Q; Zhang H; Ding J; Liu H; Li H; Li H; Lu M; Miao Y; Li L; Zheng J
    J Immunol Res; 2018; 2018():4263520. PubMed ID: 30410941
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.
    Li J; Hu H; Lian H; Yang S; Liu M; He J; Cao B; Chen D; Hu Y; Zhi C; Shen Y; Ye X; He B; Zhao M; Fan W; Xu L; Leidner R; Wu Q; Yang L; Zhang Z
    Int J Biol Sci; 2024; 20(5):1578-1601. PubMed ID: 38481806
    [No Abstract]   [Full Text] [Related]  

  • 10. Effective Targeting of TAG72
    Murad JP; Kozlowska AK; Lee HJ; Ramamurthy M; Chang WC; Yazaki P; Colcher D; Shively J; Cristea M; Forman SJ; Priceman SJ
    Front Immunol; 2018; 9():2268. PubMed ID: 30510550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fourth-generation chimeric antigen receptor T cells targeting folate receptor alpha antigen expressed on breast cancer cells for adoptive T cell therapy.
    Luangwattananun P; Junking M; Sujjitjoon J; Wutti-In Y; Poungvarin N; Thuwajit C; Yenchitsomanus PT
    Breast Cancer Res Treat; 2021 Feb; 186(1):25-36. PubMed ID: 33389403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB).
    Song DG; Ye Q; Carpenito C; Poussin M; Wang LP; Ji C; Figini M; June CH; Coukos G; Powell DJ
    Cancer Res; 2011 Jul; 71(13):4617-27. PubMed ID: 21546571
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined CD28 and 4-1BB Costimulation Potentiates Affinity-tuned Chimeric Antigen Receptor-engineered T Cells.
    Drent E; Poels R; Ruiter R; van de Donk NWCJ; Zweegman S; Yuan H; de Bruijn J; Sadelain M; Lokhorst HM; Groen RWJ; Mutis T; Themeli M
    Clin Cancer Res; 2019 Jul; 25(13):4014-4025. PubMed ID: 30979735
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic preclinical evaluation of CD33-directed chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia defines optimized construct design.
    Qin H; Yang L; Chukinas JA; Shah N; Tarun S; Pouzolles M; Chien CD; Niswander LM; Welch AR; Taylor N; Tasian SK; Fry TJ
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34531250
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ligand-based adoptive T cell targeting CA125 in ovarian cancer.
    Zhao H; Wu L; Dai J; Sun K; Zi Z; Guan J; Zhang L
    J Transl Med; 2023 Sep; 21(1):596. PubMed ID: 37670338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential lung attack and lethality generated by EpCAM-specific CAR-T cells in immunocompetent mouse models.
    Qin D; Li D; Zhang B; Chen Y; Liao X; Li X; Alexander PB; Wang Y; Li QJ
    Oncoimmunology; 2020 Aug; 9(1):1806009. PubMed ID: 32923168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Regional Delivery of Chimeric Antigen Receptor-Engineered T Cells Effectively Targets HER2
    Priceman SJ; Tilakawardane D; Jeang B; Aguilar B; Murad JP; Park AK; Chang WC; Ostberg JR; Neman J; Jandial R; Portnow J; Forman SJ; Brown CE
    Clin Cancer Res; 2018 Jan; 24(1):95-105. PubMed ID: 29061641
    [No Abstract]   [Full Text] [Related]  

  • 18. Construction of CAR-T cells targeting TM4SF1 and its anti-tumor capacity in ovarian cancer.
    Shen Y; Liu G; Zhang Q; Tian X; Ouyang L; Zhang L
    Immunol Lett; 2023 Mar; 255():1-9. PubMed ID: 36739093
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secretion of 4-1BB Ligand Crosslinked to PD-1 Checkpoint Inhibitor Potentiates Chimeric Antigen Receptor T Cell Solid Tumor Efficacy.
    Dunn ZS; Qu Y; MacMullan M; Chen X; Cinay G; Wang P
    Hum Gene Ther; 2023 Nov; 34(21-22):1145-1161. PubMed ID: 36851890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.
    Lanitis E; Poussin M; Klattenhoff AW; Song D; Sandaltzopoulos R; June CH; Powell DJ
    Cancer Immunol Res; 2013 Jul; 1(1):43-53. PubMed ID: 24409448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.